245 related articles for article (PubMed ID: 27033349)
1. Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy.
Corvo ML; Mendo AS; Figueiredo S; Gaspar R; Larguinho M; Guedes da Silva MF; Baptista PV; Fernandes AR
Pharm Res; 2016 Jun; 33(6):1351-8. PubMed ID: 27033349
[TBL] [Abstract][Full Text] [Related]
2. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
3. A Chimeric Cetuximab-Functionalized Corona as a Potent Delivery System for Microtubule-Destabilizing Nanocomplexes to Hepatocellular Carcinoma Cells: A Focus on EGFR and Tubulin Intracellular Dynamics.
Poojari R; Kini S; Srivastava R; Panda D
Mol Pharm; 2015 Nov; 12(11):3908-23. PubMed ID: 26426829
[TBL] [Abstract][Full Text] [Related]
4. In vitro and in vivo biological characterization of the anti-proliferative potential of a cyclic trinuclear organotin(iv) complex.
Martins M; Baptista PV; Mendo AS; Correia C; Videira P; Rodrigues AS; Muthukumaran J; Santos-Silva T; Silva A; da Silva MF; Gigante J; Duarte A; Gajewska M; Fernandes AR
Mol Biosyst; 2016 Mar; 12(3):1015-23. PubMed ID: 26842219
[TBL] [Abstract][Full Text] [Related]
5. In vitro characterization of a liposomal formulation of celecoxib containing 1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol, and polyethylene glycol and its functional effects against colorectal cancer cell lines.
Erdoğ A; Putra Limasale YD; Keskin D; Tezcaner A; Banerjee S
J Pharm Sci; 2013 Oct; 102(10):3666-77. PubMed ID: 23897281
[TBL] [Abstract][Full Text] [Related]
6. Biological characterization of the antiproliferative potential of Co(II) and Sn(IV) coordination compounds in human cancer cell lines: a comparative proteomic approach.
Silva A; Luís D; Santos S; Silva J; Mendo AS; Coito L; Silva TF; da Silva MF; Martins LM; Pombeiro AJ; Borralho PM; Rodrigues CM; Cabral MG; Videira PA; Monteiro C; Fernandes AR
Drug Metabol Drug Interact; 2013; 28(3):167-76. PubMed ID: 23800656
[TBL] [Abstract][Full Text] [Related]
7. Celastrol-Loaded Galactosylated Liposomes Effectively Inhibit AKT/c-Met-Triggered Rapid Hepatocarcinogenesis in Mice.
Chen X; Hu X; Hu J; Qiu Z; Yuan M; Zheng G
Mol Pharm; 2020 Mar; 17(3):738-747. PubMed ID: 31904241
[TBL] [Abstract][Full Text] [Related]
8. pH-Sensitive PEGylated liposomes for delivery of an acidic dinitrobenzamide mustard prodrug: Pathways of internalization, cellular trafficking and cytotoxicity to cancer cells.
Yang MM; Wilson WR; Wu Z
Int J Pharm; 2017 Jan; 516(1-2):323-333. PubMed ID: 27871834
[TBL] [Abstract][Full Text] [Related]
9. Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation.
Pathak P; Dhawan V; Magarkar A; Danne R; Govindarajan S; Ghosh S; Steiniger F; Chaudhari P; Gopal V; Bunker A; Róg T; Fahr A; Nagarsenker M
Int J Pharm; 2016 Jul; 509(1-2):149-158. PubMed ID: 27231122
[TBL] [Abstract][Full Text] [Related]
10. The antitumour activities induced by pegylated liposomal cytochalasin D in murine models.
Huang FY; Mei WL; Li YN; Tan GH; Dai HF; Guo JL; Wang H; Huang YH; Zhao HG; Zhou SL; Li L; Lin YY
Eur J Cancer; 2012 Sep; 48(14):2260-9. PubMed ID: 22257793
[TBL] [Abstract][Full Text] [Related]
11. Increased tumor targeted delivery using a multistage liposome system functionalized with RGD, TAT and cleavable PEG.
Mei L; Fu L; Shi K; Zhang Q; Liu Y; Tang J; Gao H; Zhang Z; He Q
Int J Pharm; 2014 Jul; 468(1-2):26-38. PubMed ID: 24709209
[TBL] [Abstract][Full Text] [Related]
12. Transporter occluded-state conformation-induced endocytosis: Amino acid transporter ATB
Luo Q; Gong P; Sun M; Kou L; Ganapathy V; Jing Y; He Z; Sun J
J Control Release; 2016 Dec; 243():370-380. PubMed ID: 27810556
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a liposome-based formulation of oxaliplatin using capillary electrophoresis: encapsulation and leakage.
Franzen U; Nguyen TT; Vermehren C; Gammelgaard B; Ostergaard J
J Pharm Biomed Anal; 2011 Apr; 55(1):16-22. PubMed ID: 21282028
[TBL] [Abstract][Full Text] [Related]
14. PEGylated liposomes modified with LHRH analogs for tumor targeting.
He Y; Zhang L; Song C
J Control Release; 2011 Nov; 152 Suppl 1():e29-31. PubMed ID: 22195906
[No Abstract] [Full Text] [Related]
15. Vascular targeting of doxorubicin using cationic liposomes.
Wu J; Lee A; Lu Y; Lee RJ
Int J Pharm; 2007 Jun; 337(1-2):329-35. PubMed ID: 17275230
[TBL] [Abstract][Full Text] [Related]
16. Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide.
Garg A; Tisdale AW; Haidari E; Kokkoli E
Int J Pharm; 2009 Jan; 366(1-2):201-10. PubMed ID: 18835580
[TBL] [Abstract][Full Text] [Related]
17. PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.
Shavi GV; Sreenivasa Reddy M; Raghavendra R; Nayak UY; Kumar AR; Deshpande PB; Udupa N; Behl G; Dave V; Kushwaha K
J Liposome Res; 2016; 26(1):28-46. PubMed ID: 25853340
[TBL] [Abstract][Full Text] [Related]
18. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
19. Augmented Anticancer Effects of Cantharidin with Liposomal Encapsulation: In Vitro and In Vivo Evaluation.
Zhang X; Lin CC; Chan WK; Liu KL; Yang ZJ; Zhang HQ
Molecules; 2017 Jun; 22(7):. PubMed ID: 28672816
[TBL] [Abstract][Full Text] [Related]
20. RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.
Wang F; Chen L; Zhang R; Chen Z; Zhu L
J Control Release; 2014 Dec; 196():222-33. PubMed ID: 25456829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
